The Role of Age on Dose-Limiting Toxicities (DLTs) in Phase I Dose-Escalation Trials.

Journal of Clinical Oncology - United States
doi 10.1200/jco.2013.31.15_suppl.9517
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Clinical Oncology (ASCO)

Related search

Correction: The Impact of Non-Drug-Related Toxicities on the Estimation of the Maximum Tolerated Dose in Phase I Trials

Clinical Cancer Research
Cancer ResearchOncology
2012English

Operating Characteristics of Restrictions on Skipping Dose Level for Adaptive Dose-Finding Method in Two-Agent Phase I Trials

Japanese Journal of Biometrics
2015English

A Phase I/Ii Seamless Dose Escalation/Expansion With Adaptive Randomization Scheme (SEARS)

Clinical Trials
MedicinePharmacology
2013English

Relationship Between Response and Dose in Published, Contemporary Phase I Oncology Trials

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2020English

Escalation Strategies for Combination Therapy Phase I Trials

Pharmaceutical Statistics
StatisticsProbabilityPharmacology
2012English

A Dose-Schedule Finding Design for Phase I-Ii Clinical Trials

Journal of the Royal Statistical Society. Series C: Applied Statistics
UncertaintyStatisticsProbability
2015English

Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2011English

A Phase I Dose-Escalation Study of Intravenous Panobinostat in Patients With Lymphoma and Solid Tumors

Investigational New Drugs
OncologyPharmacology
2013English

A Phase I Dose-Escalation Study of a Biosimilar Trastuzumab in Chinese Metastasis Breast Cancer Patients

SpringerPlus
Multidisciplinary
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy